Bibliography
- Major outcomes in high-riskantihypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). The ALLHAT officers and coordinators for the ALLHAT collaborative research group. JAMA (2002) 288:2981–2997.
- WING LMH, REID CM, RYAN P et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. The second Australian national blood pressure study group. N Ergd j Med. (2003) 348:583–592.
- PSATY BM, SMITH NL, SISCOVICK DS et al.: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA (1997) 277:739–745.
- NEAL B, MACMAHON S, CHAPMAN N: Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. The blood pressure lowering treatment trialists' collaboration. Lancet (2000) 356:1955–1964.
- Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT collaborative research group. JAMA (2000) 283:1967–1975.
- Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). The ALLHAT officers and coordinators for the ALLHAT collaborative research group. JAMA (2002) 288:2998–3007.
- APPERLOW AJ, DE ZEEUW, DE JONG PE: Discordant effect of enalapril and lisinopril on systemic and renal hemodynamics. Clin. Pharmacy]. Ther. (1994) 56:647–658.
- Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Eng]. J. Med. (2000) 342:142–153.
- DAHLOF B, DEVEREUX RB, KJEDLSEN SE et al.: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23:995–1003.